Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Lisa A. Kottschade
Sex Differences in Tolerability to Anti‐Programmed Cell Death Protein 1 Therapy in Patients With Metastatic Melanoma and Non‐Small Cell Lung Cancer: Are We All Equal?
Oncologist
Cancer Research
Medicine
Oncology
Related publications
P1.01-17 Immune-Related Adverse Events in Patients With Metastatic Non-Small Cell Lung Cancer: Sex Differences and Response to Therapy
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Real‐World Outcomes of Patients With Metastatic Non‐Small Cell Lung Cancer Treated With Programmed Cell Death Protein 1 Inhibitors in the Year Following U.S. Regulatory Approval
Oncologist
Cancer Research
Medicine
Oncology
Prognostic Value of Red Blood Cell Distribution Width in Non-Small Cell Lung Cancer Treated With Anti-Programmed Cell Death-1 Antibody
In Vivo
Biochemistry
Medicine
Genetics
Pharmacology
Molecular Biology
Cutaneous Adverse Events (AEs) of Anti-Programmed Cell Death (PD)-1 Therapy in Patients With Metastatic Melanoma: A Single-Institution Cohort
Journal of the American Academy of Dermatology
Dermatology
Anti-Programmed Cell Death Protein-1/Ligand-1 Therapy in Different Cancers
British Journal of Cancer
Cancer Research
Oncology
MicroRNAs Aid the Assessment of Programmed Death Ligand�1 Expression in Patients With Non‑small Cell Lung Cancer
Oncology Letters
Cancer Research
Oncology
Programmed Death-Ligand 1 Immunohistochemistry Testing for Non-Small Cell Lung Cancer in Practice
Cancer cytopathology
Cancer Research
Oncology
Prognostic Impact of CD8 and Programmed Death-Ligand 1 Expression in Patients With Resectable Non-Small Cell Lung Cancer
British Journal of Cancer
Cancer Research
Oncology
Petals and Thorns in Programmed Death-Ligand 1 Testing: Is All Non-Small Cell Lung Cancer Diagnostic Material Suitable?
Cancer cytopathology
Cancer Research
Oncology
